

Advanced Enzyme Technologies Ltd.

CIN: L24200MH1989PLC051018

Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India

Tel: +91-22-4170 3200, Fax: +91-22-2583 5159

Email: info@advancedenzymes.com, www.advancedenzymes.com

November 12, 2025

BSE Limited

P. J. Towers,
Dalal Street,
Mumbai- 400 001

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (E) Mumbai- 400 051

Scrip Code-540025

Trading Symbol-ADVENZYMES

Dear Sir,

Subject: Outcome of Board Meeting held on November 12, 2025.

Ref: ISIN: INE837H01020

With reference to the notice of Board Meeting dated November 04, 2025, we hereby inform that the Board of Directors at its Meeting held on November 12, 2025 (commenced at 9.50 a.m. and concluded at 10.15 a.m.) has *inter alia*, transacted the following business:

- Approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.

In view of the aforesaid, we are enclosing the following:

- Annexure I - Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2025 along with the Limited Review report issued by MSKA & Associates, Statutory Auditors of the Company as an Annexure.

The aforesaid financial results and other documents are also being uploaded on the website of the Company i.e. www.advancedenzymes.com

This is for your information and for public at large.

Thanking you,

Yours faithfully,

For Advanced Enzyme Technologies Limited



Sanjay Basantani

Company Secretary and Head – Legal



Encl.: As above

Independent Auditor's Review Report on consolidated unaudited financial results of Advanced Enzyme Technologies Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Advanced Enzyme Technologies Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of **Advanced Enzyme Technologies Limited** (hereinafter referred to as 'the Holding Company') and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended September 30, 2025 and the year to-date results for the period from April 01, 2025 to September 30, 2025 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Advanced Bio-Agro Tech Limited	Subsidiary
2	Advanced Enzytech Solutions Limited	Wholly Owned Subsidiary
3	Advanced Enzymes USA, Inc. ('AEU')	Wholly Owned Subsidiary



MSKA & Associates

Chartered Accountants

4	Advanced Supplementary Technologies Corporation	Wholly Owned Subsidiary of AEU
5	Cal India Foods International ('CAL')	Wholly Owned Subsidiary of AEU
6	Enzyme Innovation, Inc	Wholly Owned Subsidiary of CAL
7	JC Biotech Private Limited	Subsidiary
8	Scitech Specialities Private Limited	Subsidiary
9	Advanced Enzymes Europe B.V. ('AEEBV')	Wholly Owned Subsidiary
10	Evoxx Technologies GmbH	Wholly Owned Subsidiary of AEEBV
11	Saiganesh Enzytech Solutions Private Limited	Subsidiary
12	Starya Labs Inc.	Wholly Owned Subsidiary of AEU
13	Advanced Nutrazyme Private Limited	Wholly Owned Subsidiary (with effect from July 04, 2025)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of four subsidiaries included in the Statement, whose interim financial results reflects total assets of Rs. 1,954.23 million as at September 30, 2025 and total revenues of Rs. 564.19 million and Rs. 1,133.05 million, total net profit after tax of Rs. 61.96 million and Rs. 91.72 million and total comprehensive income of Rs. 62.64 million and Rs. 92.00 million for the quarter ended September 30, 2025 and for the period from April 01, 2025 to September 30, 2025 respectively, and cash inflows (net) of Rs. 9.41 million for the period from April 01, 2025 to September 30, 2025, as considered in the Statement. These interim financial results have been reviewed by the other auditors whose reports have been furnished to us by the management, and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

7. One subsidiary is located outside India whose interim financial results has been prepared in accordance with the accounting principles generally accepted in their respective country and which has been reviewed by other auditor under generally accepted auditing standards applicable in their respective country. The Holding Company's Management has converted the interim financial results of such subsidiary located outside India from accounting principles generally accepted in their respective country to accounting principles generally accepted in India.



MSKA & Associates

Chartered Accountants

We have reviewed these conversion adjustments made by the Holding Company's Management. Our conclusion on the Statement, in so far as it relates to the interim financial results of such subsidiary, located outside India is based on the report of other auditor and the conversion adjustments prepared by the Management of the Holding Company and reviewed by us.

Our conclusion is not modified in respect of the above matter.

8. The Statement includes the interim financial results of four subsidiaries which have not been reviewed by their auditors, whose interim financial results reflects total assets of Rs. 1,252.67 million as at September 30, 2025 and total revenue of Rs. 72.78 million and Rs. 162.42 million, total net profit after tax of Rs. 8.29 million and Rs. 20.86 million and total comprehensive income of Rs. 8.29 million and Rs. 20.86 million for the quarter ended September 30, 2025 and for the period from April 01, 2025 to September 30, 2025, respectively, and cash flows (net) of Rs. 3.78 million for the period from April 01, 2025 to September 30, 2025, as considered in the Statement. These interim financial results have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Amrish Vaidya

Partner

Membership No.: 101739

UDIN: 25101739BMMKNA2533



Place: Mumbai

Date: November 12, 2025

Statement of unaudited consolidated financial results for the quarter and six months ended 30 September 2025

(Rs in Million except per share data)

Particulars	Quarter ended			Six months ended		Year ended
	30-Sep-25 Unaudited	30-Jun-25 Unaudited	30-Sep-24 Unaudited	30-Sep-25 Unaudited	30-Sep-24 Unaudited	31-Mar-25 Audited
1 Revenue from operations						
2 Other Income	1,845.28	1,859.14	1,460.95	3,704.42	3,006.19	6,369.10
3 Total Income (1+2)	102.84	88.50	96.18	191.34	166.11	330.41
4 Expenses	1,948.12	1,947.64	1,557.13	3,895.76	3,172.30	6,699.51
(a) Cost of materials consumed						
(b) Purchases of stock-in-trade #	487.42	439.70	390.53	927.12	792.50	1,619.56
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	-	-	0.00	-	-
(d) Employee benefits expense (refer note iv)	(41.75)	60.79	(63.57)	19.04	(123.10)	(100.95)
(e) Finance costs (including exchange difference)	393.73	397.13	355.23	790.86	701.82	1,415.42
(f) Depreciation and amortisation expense	7.22	7.64	9.29	14.86	18.03	35.57
(g) Other expenses	100.76	96.18	88.95	196.94	175.08	365.56
Total Expenses	405.33	397.20	354.61	802.53	699.15	1,490.71
5 Profit before exceptional item and tax (3-4)	1,352.71	1,398.64	1,135.04	2,751.35	2,263.48	4,825.87
6 Exceptional item	595.41	549.00	422.09	1,144.41	908.82	1,873.64
7 Profit before tax (5-6)	-	-	-	-	-	-
8 Tax expense	595.41	549.00	422.09	1,144.41	908.82	1,873.64
Current tax						
Deferred tax charge / (credit)	156.92	154.70	86.84	311.62	215.64	495.33
Total tax expense	(8.84)	(10.10)	1.32	(18.94)	9.49	38.57
9 Net profit for the period (7-8)	148.08	144.60	88.16	292.68	225.13	533.90
10 Other comprehensive income	447.33	404.40	333.93	851.73	683.69	1,339.74
A (i) Items that will not be reclassified to profit or loss						
Remeasurements of defined benefit liability/(asset)	0.95	(0.57)	(1.86)	0.38	(1.93)	(6.78)
(ii) Income tax related to items that will not be reclassified to profit or loss	(0.27)	0.16	0.51	(0.11)	0.53	1.77
B (i) Items that will be reclassified to profit or loss						
Exchange differences in translating financial statements of foreign operations	311.39	38.12	50.36	349.51	52.27	193.23
(ii) Income tax related to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive income	312.07	37.71	49.01	349.78	50.87	188.22
11 Total comprehensive income (9+10)	759.40	442.11	382.94	1,201.51	734.56	1,527.96
12 Net profit attributable to:						
Shareholders of the Company	433.26	399.30	328.33	832.56	669.85	1,311.15
Non-controlling interest	14.07	5.10	5.60	19.17	13.84	28.59
13 Other comprehensive income attributable to:						
Shareholders of the Company	312.04	37.73	49.14	349.77	50.93	188.26
Non-controlling interest	0.03	(0.02)	(0.13)	0.01	(0.06)	(0.04)
14 Total comprehensive income attributable to:						
Shareholders of the Company	745.30	437.03	377.47	1,182.33	720.78	1,499.41
Non-controlling interest	14.10	5.08	5.47	19.18	13.78	28.55
15 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.76	223.76	223.65	223.76	223.65	223.76
16 Other equity						
17 Earnings Per Share of ₹ 2 each (not annualized)						
(a) ₹ (Basic)	3.87	3.57	2.94	7.44	5.99	11.72
(b) ₹ (Diluted)	3.87	3.57	2.93	7.43	5.98	11.71

Figures are below Rs. 0.01 Million, hence disclosed as Rs. 0.00



20.09.2025

Statement of consolidated assets and liabilities

		(₹ in million)	
Particulars		As at 30 September 2025	As at 31 March 2025
		Unaudited	Audited
I. ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment		2,844.47	2,929.41
(b) Capital work-in-progress		310.25	216.91
(c) Goodwill		3,480.87	3,334.40
(d) Other Intangible assets		504.12	522.91
(e) Intangible assets under development		0.22	0.17
(f) Financial Assets			
(i) Investments		0.64	0.65
(ii) Loans		0.05	0.65
(ii) Other financial assets		41.94	99.19
(g) Deferred tax assets (net)		117.47	101.92
(h) Income tax assets (net)		223.66	177.69
(i) Other non-current assets		60.67	30.88
Total non-current assets		7,584.36	7,414.78
(2) Current Assets			
(a) Inventories		1,734.23	1,573.05
(b) Financial Assets			
(i) Investments		5,292.73	4,802.58
(ii) Trade receivables		1,252.77	1,153.99
(iii) Cash and cash equivalents		623.57	942.25
(iv) Bank balances other than (iii) above		140.67	134.60
(v) Loans		2.85	1.03
(vi) Other financial assets		133.14	80.48
(c) Other current assets		154.64	110.71
Total current assets		9,334.60	8,798.69
Total assets		16,918.96	16,213.47
II. EQUITY AND LIABILITIES			
(1) Equity			
(a) Equity share capital		223.76	223.76
(b) Other equity		14,621.69	13,984.87
Equity attributable to the owners of the Company		14,845.45	14,208.63
Non-controlling interest		490.25	478.07
Total equity		15,335.70	14,686.70
(3) Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings		86.89	91.83
(ii) Lease liability		72.46	117.34
(b) Provisions		18.78	13.71
(c) Deferred tax liabilities (net)		337.82	336.34
Total non-current liabilities		515.95	559.22
(4) Current liabilities			
(a) Financial liabilities			
(i) Borrowings		109.60	123.53
(ii) Lease liability		77.59	60.80
(iii) Trade payables			
a) total outstanding dues of micro enterprises and small enterprises		30.61	42.93
b) total outstanding dues of creditors other than micro enterprises and small enterprises		262.40	129.08
(iv) Other financial Liabilities		253.05	266.33
(b) Other current liabilities		118.19	85.28
(c) Provisions		202.91	213.68
(d) Current tax liabilities (net)		12.96	45.92
Total current liabilities		1,067.31	967.55
Total equity and liabilities		16,918.96	16,213.47



Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

STATEMENT OF CASHFLOW

(₹ in million)

		For six months ended 30 September 2025 Unaudited	For six months ended 30 September 2024 Unaudited
A.	Cash flows from operating activities		
	Profit before tax	1144.41	908.82
		1144.41	908.82
	Adjustments for non-cash transactions		
	Depreciation and amortization expense	196.94	175.08
	Prepaid lease amortisation	0.09	0.09
	(Profit)/Loss on sale of Property, plant and equipments	1.63	(0.68)
	Allowances for bad and doubtful trade receivables	(4.53)	3.72
	Bad and doubtful trade receivables written off	1.66	1.17
	Employee stock compensation expense	29.07	21.10
	Excess provision written back	0.05	(1.98)
	Sundry balances written (back)/ off (net)	0.02	(0.04)
	Fair valuation of investments in marketable securities	(82.35)	(74.67)
	Provision for inventory	5.91	1.21
	Unrealized foreign exchange (gain)/ loss	(8.05)	(1.22)
		1,284.85	1,032.60
	Items considered separately		
	Interest income	(70.36)	(84.82)
	Interest expenses	14.83	18.22
	Operating profit before working capital changes	1,229.32	966.00
	Adjustments for:		
	(Increase) / Decrease in non-current loans	1.75	(0.35)
	(Increase) / Decrease in other non-current financial assets	0.01	(1.27)
	(Increase) / Decrease in other non-current assets	0.31	6.94
	(Increase) / Decrease in inventories	(141.66)	(196.83)
	(Increase) / Decrease in trade receivables	(76.55)	(3.61)
	(Increase) / Decrease in current loans	(1.83)	0.06
	(Increase) / Decrease in financial current assets	(46.86)	44.36
	(Increase) / Decrease in other current assets	(41.89)	(27.74)
	(Decrease) / Increase in provisions	(11.59)	(52.46)
	(Decrease) / Increase in trade payables	111.09	67.07
	(Decrease) / Increase in current financial liabilities - others	(4.00)	(0.02)
	(Decrease) / Increase in other current liabilities	19.10	47.00
	Cash generated from operating activities	1037.40	849.15
	Income taxes paid (net of refund)	(390.27)	(419.59)
	Net cash generated from operating activities	647.13	429.56
B.	Cash flows from investing activities		
	Purchase of property, plant and equipment	(183.38)	(202.79)
	Proceeds from sale of property, plant and equipment's	2.77	1.68
	Capital expenditure on intangible assets under development	-	(9.83)
	Purchase of intangible assets (net of refund)	(1.69)	(0.88)
	(Purchase) / Proceeds from sale of current investments (net)	(240.42)	162.72
	Interest received	65.16	83.64
	(Increase) in bank deposits with maturity more than 3 months but less than 12 months	(5.30)	(1.74)
	(Increase) / Decrease in bank deposits with maturity of more than 12 months	55.60	(0.00)
	Net cash generated from investing activities	(307.26)	32.80
C.	Cash flows from financing activities		
	Proceeds from issue of share capital including securities premium	7.21	3.70
	Repayment of long-term borrowings (net)	(4.89)	(2.74)
	(Repayment)/proceeds from short-term borrowings (net)	(13.97)	8.50
	Interest paid	(13.84)	(17.23)
	Lease liability paid	(38.56)	(33.57)
	Dividends paid	(588.78)	(582.30)
	Net cash (used in) financing activities	(652.83)	(623.64)
	Net (decrease) / increase in cash and cash equivalents (A+B+C)	(312.96)	(161.28)
	Cash and cash equivalents as at the beginning of the year	942.25	1137.51
	Effect of exchange rate changes on cash and cash equivalents held	(5.72)	1.60
	Cash and cash equivalents as at the end of the period	623.57	977.83
	Composition of cash and cash equivalents		
	Cash in hand		
	Balance with banks :	0.98	0.62
	Current account	302.13	272.11
	Fixed deposit account (with maturity less than 3 months)	3.74	96.93
	Liquid fund balance (with maturity less than 3 months)	316.72	608.17
		623.57	977.83

Figures are below Rs 0.01 Million, hence disclosed as Rs 0.00

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

- (i) The above unaudited consolidated financial results include the financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India), Saiganesh Enzytech Solutions Private Limited (India), Advanced Nutrazyme Private Limited (India)(w.e.f. 4 July 2025), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Starya Labs, Inc. (w.e.f. 09 December 2024), Advanced Enzymes Europe B.V. (Netherlands) and Evoxx Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".
- (ii) The above unaudited consolidated financial results of the Group were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 12 November 2025. The above results have been reviewed by the statutory auditors of the Company and they have expressed an unmodified conclusion. The limited review report will be filed with stock exchanges and will be available on the Company's website. The above results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- (iii) The Group operates only in one business segment viz. 'manufacturing and sales of enzymes'.
- (iv) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 576,000 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 12 August 2023, approved by Nomination and Remuneration Committee of the Board. The Company has further granted 512,500 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 27 March 2025, approved by Nomination and Remuneration Committee of the Board.
- (v) The Group has allotted 57,075 equity shares during the year ended 31 March 2025 to employees under the 'Employee Stock Option Scheme 2022'- ("ESOP Scheme 2022").
- (vi) On 19 December 2024, the Company invested Rs 478.18 million in Advanced Enzymes Europe B.V. ('AEEBV') (wholly owned subsidiary) by way of subscription to 3,623,163 equity shares. The value per equity share is EUR 1.48 and the face value of EUR 1 per share. Pursuant to this conversion, the Company now holds 7,900,000 equity share of AEEBV and the Company continues to be 100% shareholder of AEEBV.
- (vii) The Board of Directors of the Company declared and paid interim dividend of Rs 4/- per equity share during the quarter ended 30 June 2025.
- (viii) The Board of Directors in its meeting held on 13 May 2025 have proposed the final dividend for the financial year 2024-25 of Rs 1.20/- per equity share and the same is approved by the shareholders of the Company in its Annual General Meeting held on 30 July 2025 and paid on 5 August 2025.
- (ix) The Company has incorporated a new wholly owned subsidiary by name of Advanced Nutrazyme Private Limited ('ANPL'), the subsidiary received its certificate of incorporation on 4 July 2025. ANPL will be engaged in the business of sales and distribution of the Company's Nutrition and Wellness range of products.
- (x) The Company is closely monitoring recent developments regarding the imposition of tariffs by the Government of United States of America ('USA') on imports of enzymes from India. Our subsidiaries based in USA are actively engaging with its customers to manage the impact of tariffs on end customers. Given the evolving nature of the situation, the Company will continue to assess the developments and also assess the potential impact on its financial position. As at and for the period ended September 2025, these developments had no material impact on the Company's financial results.
- (xi) Previous period's figures have been regrouped / reclassified where necessary.



By Order of the Board of Directors
For Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018

M.M. Kabra

M.M. Kabra
Wholtime Director
DIN : 00148294

Place: Thane
Dated: 12 November 2025

Independent Auditor's Review Report on Standalone unaudited financial results of Advanced Enzyme Technologies Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.


To The Board of Directors of Advanced Enzyme Technologies Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Advanced Enzyme Technologies Limited (hereinafter referred to as 'the Company') for the quarter ended September 30, 2025 and the year to-date results for the period from April 01, 2025 to September 30, 2025 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Amrish Vaidya
Partner

Membership No.: 101739

UDIN:25101739BM1KMZ2105



Place: Mumbai

Date: November 12, 2025

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.


Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Statement of unaudited standalone financial results for the quarter and six months ended 30 September 2025

(Rs in Million except per share data)

	Particulars	Quarter ended			Six months ended		Year ended
		30-Sep-25 Unaudited	30-Jun-25 Unaudited	30-Sep-24 Unaudited	30-Sep-25 Unaudited	30-Sep-24 Unaudited	31-Mar-25 Audited
1	Revenue from operations	1,157.48	1,250.24	773.78	2,407.72	1,633.35	3,514.11
2	Other Income	30.79	538.52	16.55	569.31	555.31	614.90
3	Total Income (1+2)	1,188.27	1,788.76	790.33	2,977.03	2,188.66	4,129.01
4	Expenses						
(a)	Cost of materials consumed	483.24	518.99	371.72	1,002.23	747.52	1,488.00
(b)	Purchases of stock-in-trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(22.73)	43.56	(80.62)	20.83	(142.20)	(64.67)
(d)	Employee benefits expense (refer note iii)	160.62	162.07	139.47	322.69	281.37	560.35
(e)	Finance costs (including exchange difference)	0.49	0.53	0.76	1.02	0.98	2.36
(f)	Depreciation and amortisation expense	30.02	29.29	27.84	59.31	54.03	114.05
(g)	Other expenses	240.44	220.36	207.95	460.80	402.19	823.64
	Total expenses	892.08	974.80	667.12	1,866.88	1,343.89	2,923.73
5	Profit before exceptional item and tax (3-4)	296.19	813.96	123.21	1,110.15	844.77	1,205.28
6	Exceptional item	-	-	-	-	-	-
7	Profit before tax (5-6)	296.19	813.96	123.21	1,110.15	844.77	1,205.28
8	Tax expense						
	Current tax	72.83	74.41	30.66	147.24	80.12	168.86
	Deferred tax charge/(credit)	0.54	(0.26)	1.29	0.28	2.83	12.22
	Total tax expense	73.37	74.15	31.95	147.52	82.95	181.08
9	Net profit for the period (7-8)	222.82	739.81	91.26	962.63	761.82	1,024.20
10	Other comprehensive income						
A (i)	Items that will not be reclassified to Profit or Loss						
	Remeasurements of defined benefit liability/(asset)	-	-	-	-	-	(4.60)
(ii)	Income tax related to items that will not be reclassified to Profit or Loss	-	-	-	-	-	1.16
B (i)	Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
(ii)	Income tax related to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	Total Other comprehensive income	-	-	-	-	-	(3.44)
11	Total comprehensive income (9+10)	222.82	739.81	91.26	962.63	761.82	1,020.76
12	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.76	223.76	223.65	223.76	223.65	223.76
13	Other equity						6,069.65
14	Earnings Per Share of ₹ 2 each (not annualized)						
(a)	₹ (Basic)	1.99	6.61	0.82	8.60	6.82	9.16
(b)	₹ (Diluted)	1.99	6.61	0.81	8.59	6.80	9.15



W. W. Karm

Statement of standalone assets and liabilities

		(₹ in million)	
Particulars		As at 30-Sep-25 Unaudited	As at 31-Mar-25 Audited
I. ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment		1,468.65	1,508.82
(b) Capital work-in-progress		309.54	207.35
(c) Other Intangible assets		54.58	56.18
(d) Intangible assets under development		0.22	0.17
(e) Financial Assets			
(i) Investments			
- Investment in subsidiaries		2,540.81	2,536.50
- other investment		0.62	0.62
(ii) Loans		0.06	0.65
(iii) Other financial assets		23.65	79.26
(f) Income tax asset (net)		179.88	160.00
(g) Other non-current assets		35.49	14.77
Total non-current assets		4,613.50	4,564.32
(2) Current Assets			
(a) Inventories		1,026.08	1,014.50
(b) Financial Assets			
(i) Investments		552.74	366.52
(ii) Trade receivables		1,025.16	781.69
(iii) Cash and cash equivalents		74.55	56.04
(iv) Bank balances other than (iii) above		6.36	2.28
(v) Loans		1.54	0.26
(vi) Other financial assets		111.58	48.81
(c) Other current assets		82.95	51.89
Total current assets		2,880.96	2,321.99
Total assets		7,494.46	6,886.31
II. EQUITY AND LIABILITIES			
(1) Equity			
(a) Equity share capital		223.76	223.76
(b) Other equity		6,486.77	6,069.65
Total equity		6,710.53	6,293.41
(2) Non-current liabilities			
(a) Financial liabilities			
(i) Lease liability		15.25	19.69
(b) Provisions		12.30	13.27
(c) Deferred tax liabilities (net)		118.28	118.00
Total non-current liabilities		145.83	150.96
(3) Current liabilities			
(a) Financial liabilities			
(i) Lease liability		8.54	7.95
(ii) Trade payables			
a) total outstanding dues of micro enterprises and small enterprises		22.07	33.30
b) total outstanding dues of creditors other than micro enterprises and small enterprises		353.60	193.46
(iii) Other financial Liabilities		149.14	134.89
(b) Other current liabilities		74.35	39.13
(c) Provisions		27.47	30.29
(d) Current tax liabilities (net)		2.93	2.92
Total current liabilities		638.10	441.94
Total equity and liabilities		7,494.46	6,886.31



W. W. K. K. K.



Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

STATEMENT OF STANDALONE CASH FLOW

	For six months ended 30 September 2025 Rs. in million Unaudited	For six months ended 30 September 2024 Rs. in million Unaudited
A. Cash flows from operating activities		
Profit before tax	1,110.15	844.77
	<u>1,110.15</u>	<u>844.77</u>
Adjustments for non-cash transactions		
Depreciation and amortization expense	59.31	54.03
(Profit) / Loss on sale of property, plant and equipment	0.19	(0.42)
Bad debts written off	0.10	0.17
Provision for doubtful trade receivables provided / (written back)	(5.38)	2.50
Employee stock compensation expense	25.25	18.28
Excess provision written back	0.05	(1.98)
Sundry balances written (back) (net)	0.02	(0.04)
Unrealized foreign exchange (gain)	(8.08)	(1.22)
Fair value adjustment on investments	(28.15)	(18.24)
	<u>1,153.46</u>	<u>897.85</u>
Items considered separately		
Interest income	(4.04)	(6.39)
Interest expenses	1.02	0.98
Dividend income	(535.41)	(528.06)
Operating profit before working capital changes	<u>615.03</u>	<u>364.38</u>
Adjustments for working capital changes		
(Increase) / Decrease in Other non-current financial assets	0.01	(1.27)
(Increase) / Decrease in other non-current assets	1.06	(0.16)
(Increase) / Decrease in inventories	(11.58)	(184.15)
(Increase) / Decrease in trade receivables	(229.71)	68.85
(Increase) / Decrease in Current loans	(1.28)	0.06
(Increase) / Decrease in other current financial assets	(59.25)	40.84
(Increase) / Decrease in Other current assets	(31.06)	(19.03)
(Decrease) / Increase in provisions	(3.76)	(9.02)
(Decrease) / Increase in trade payables	148.43	58.41
(Decrease) / Increase in other current financial liabilities	11.55	0.99
(Decrease) / Increase in other current liabilities	35.22	48.87
Cash generated from operating activities	<u>474.66</u>	<u>368.77</u>
Income taxes paid (net)	(167.14)	(180.19)
Net cash generated from operating activities	<u>307.52</u>	<u>188.58</u>
B. Cash flows from investing activities		
Purchase of property, plant and equipment (tangible assets)	(138.33)	(136.04)
Proceeds from sale of property, plant and equipment	0.14	0.98
Purchase of intangible assets (net of refunds)	(1.69)	(0.85)
Purchase of non-current investments	(0.50)	-
(Purchase) / Proceeds from sale of current investments (net)	(158.07)	43.90
Interest received	1.11	3.98
Dividend received	535.41	528.06
(Increase) / Decrease in bank deposits with maturity more than 3 months but less than 12 months	(3.23)	0.30
(Increase) / Decrease in bank deposits with maturity of more than 12 months #	55.60	-
Net cash generated in investing activities	<u>290.44</u>	<u>440.33</u>
C. Cash flows from financing activities		
Proceeds from issue of share capital including securities premium	7.21	3.70
Repayment of short-term borrowings (net) #	0.00	0.00
Interest paid	(0.00)	(0.02)
Payment of Lease liabilities	(4.88)	(4.69)
Dividends paid	(581.78)	(570.30)
Net cash (used in) financing activities	<u>(579.45)</u>	<u>(571.31)</u>
Net (decrease) / increase in cash and cash equivalents (A+B+C)	<u>18.51</u>	<u>57.60</u>
Cash and cash equivalents as at the beginning of the period	56.04	14.95
Cash and cash equivalents as at the end of the period	<u>74.55</u>	<u>72.55</u>
Composition of cash and cash equivalents		
Cash in hand	0.50	0.42
Balance with banks :		
Current account	70.83	31.93
Fixed deposit account (with maturity less than 3 months)	3.22	40.20
	<u>74.55</u>	<u>72.55</u>

Figures are below Rs 0.01 Million, hence disclosed as Rs 0.00



W. W. Katre

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

(i) The above standalone financial results of Advanced Enzyme Technologies Limited ('the Company') were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 12 November 2025. The above results have been subjected to 'Limited Review' by the statutory auditors of the Company and they have expressed an unmodified conclusion. The limited review report will be filed with stock exchanges and will be available on the Company's website. The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies in India.

(ii) The Company operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(iii) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 576,000 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 12 August 2023, approved by Nomination and Remuneration Committee of the Board. The Company has further granted 512,500 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 27 March 2025, approved by Nomination and Remuneration Committee of the Board.

(iv) The Company has allotted 57,075 equity shares during the year ended 31 March 2025 to employees under the 'Employee Stock Option Scheme 2022' ("ESOP Scheme 2022").

(v) On 19 December 2024, the Company invested Rs 478.18 million in Advanced Enzymes Europe B.V. ("AEEBV") (wholly owned subsidiary) by way of subscription to 3,623,163 equity shares. The value per equity share is EUR 1.48 and the face value of EUR 1 per share. Pursuant to this conversion, the Company now holds 7,900,000 equity share of AEEBV and the Company continues to be 100% shareholder of AEEBV.

(vi) The final dividend for the financial year 2024-25 of Rs 1.20/- per equity share is paid on 5 August 2025 after approval of the shareholders of the Company in its Annual General Meeting held on 30 July 2025.

(vii) The Company has incorporated a new wholly owned subsidiary by name of Advanced Nutrazyme Private Limited ("ANPL"), the subsidiary received its certificate of incorporation on 4 July 2025. ANPL will be engaged in the business of sales and distribution of the Company's Nutrition and Wellness range of products.

(viii) Previous year / period amounts have been regrouped / reclassified wherever necessary.



By Order of the Board of Directors
For Advanced Enzyme Technologies Limited
CIN: L24200MH1989PLC051018

M. M. Kabra

M. M. Kabra
Wholetime Director
DIN : 00148294

Place: Thane

Dated: 12 November 2025